Registered title, quoted from ClinicalTrials.gov
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07668752, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
3. Histologically or cytologically confirmed locally advanced unresectable or metastatic non small cell lung cancer (NSCLC).
Inclusion criterion 3
5. Disease progression or intolerance to toxicity after at least one prior line of platinum based chemotherapy and anti PD 1/PD L1 antibody therapy.
Inclusion criterion 5
5. Prior treatment with KRAS G12D targeted therapy or pan RAS/KRAS targeted therapy.
Exclusion criterion 5
6. Prior treatment with docetaxel as part of systemic therapy.
Exclusion criterion 6
7. Radiotherapy within 4 weeks prior to randomization, or other local anti tumor therapy within 4 weeks prior to randomization.
Exclusion criterion 7
8. Other anti tumor therapy within 28 days or 5 half lives prior to randomization, or cell therapy within 3 months prior to randomization.
Exclusion criterion 8
6. At least one measurable target lesion according to RECIST version 1.1.
Inclusion criterion 6
2. Other malignancy that has progressed or required treatment within 3 years prior to randomization.
Exclusion criterion 2
14. Pregnancy or breastfeeding.
Exclusion criterion 14
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07668752, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 1. Voluntary participation in the study and signed informed consent form (ICF).
- 2. Age ≥ 18 years at the time of signing the ICF; male or female.
- 3. Histologically or cytologically confirmed locally advanced unresectable or metastatic non small cell lung cancer (NSCLC).
- 4. Participants must provide adequate and qualified tumor tissue slides samples or agree to undergo tumor biopsy to obtain tissue samples for central laboratory confirmation of KRAS G12D mutation.
- 5. Disease progression or intolerance to toxicity after at least one prior line of platinum based chemotherapy and anti PD 1/PD L1 antibody therapy.
- 6. At least one measurable target lesion according to RECIST version 1.1.
- 7. Investigator assessed life expectancy ≥ 12 weeks.
- 8. Adequate organ function.
- 9. Ability to communicate well, comply with scheduled follow up visits, and adhere to protocol requirements.
Exclusion Criteria:
- 1. Presence of other driver gene mutations in NSCLC, or concurrent other KRAS or RAS mutations.
- 2. Other malignancy that has progressed or required treatment within 3 years prior to randomization.
- 3. Leptomeningeal metastasis, or symptomatic or progressive central nervous system (CNS) metastasis.
- 4. Existing or potential severe bone injury due to bone metastasis, or uncontrolled pain related to bone metastasis.
- 5. Prior treatment with KRAS G12D targeted therapy or pan RAS/KRAS targeted therapy.
- 6. Prior treatment with docetaxel as part of systemic therapy.
- 7. Radiotherapy within 4 weeks prior to randomization, or other local anti tumor therapy within 4 weeks prior to randomization.
- 8. Other anti tumor therapy within 28 days or 5 half lives prior to randomization, or cell therapy within 3 months prior to randomization.
- 9. Clinically significant severe cardiovascular disease.
- 10. Stroke or other severe cerebrovascular disease within 6 months prior to randomization.
- 11. Major acute or chronic infectious disease.
- 12. Other poorly controlled systemic diseases.
- 13. Severe psychiatric or psychological disorder, or history of drug abuse, or severe alcohol abuse.
- 14. Pregnancy or breastfeeding.
- 15. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Quoted from ClinicalTrials.gov, NCT07668752, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07668752, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.